Ernexa Therapeutics Inc. (ERNA) intrinsic value & 10-year financials
Ernexa Therapeutics Inc. (ERNA) has a Graham intrinsic value of $125.07 per share. At $2.09 on Oct 17, 2026, the stock trades 98% below that value. Over the last 10 fiscal years revenue shrank 36.6% a year to $0, with an average return on invested capital of 452.2%.
- Graham intrinsic value
- $125.07
- Share price (Oct 17, 2026)
- $2.09
- Price vs Graham value
- 98% below
- Market cap
- $13.2M
- Revenue (FY2025)
- $0
- Revenue growth (10-yr CAGR)
- -36.6%
- ROIC (10-yr avg)
- 452.2%
- Free cash flow (FY2025)
- -$7.1M
ERNA 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $0 | -$14.1M | -$2.24 | -$7.1M | — | -1494.7% |
| FY2024 | $582.0K | -$44.5M | -$3.26 | -$16.2M | -2693.1% | -112.1% |
| FY2023 | $68.0K | -$21.7M | -$4.08 | -$20.4M | -31080.9% | -145.4% |
| FY2022 | $0 | -$24.6M | -$8.06 | -$21.3M | — | 1000.8% |
| FY2021 | — | -$122.3M | -$2.82 | -$23.6M | — | 5439.6% |
| FY2020 | $5.8M | -$4.4M | -$1.51 | -$3.9M | -108.8% | -109.2% |
| FY2019 | $19.8M | -$2.0M | — | $2.6M | -8.9% | -21.1% |
| FY2018 | $23.3M | -$259.0K | — | $717.0K | 0.9% | 1.5% |
| FY2017 | $21.3M | -$1.1M | — | -$179.0K | -6.6% | -12.9% |
| FY2016 | $22.3M | -$2.9M | — | -$404.0K | -10.2% | -24.0% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Ernexa Therapeutics Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Ernexa Therapeutics Inc. has historically struggled to out-earn its cost of capital, averaging just -37.4% ROIC.
Ernexa Therapeutics Inc. has not shown aggressive share repurchases (>10% retirement) or a major balance-sheet leverage increase (>50% net debt growth) over the 10-year window.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Ernexa Therapeutics Inc. is modeled at -36.6% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $125.07 per share.